back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2026-03-17 14:58 Tx date 2026-03-13 |
$SHRX
Sharp Therapeutics Corp. |
Hathaway, John J.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: STX Partners, LLC (Control or Direction)
|
Convertible Notes (US$)
16 - Acquisition or disposition under a prospectus exemption
|
+$200,000 vol |
$400,000 | |
| Filed 2026-03-04 20:41 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Hathaway, John J.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: STX Partners, LLC (Control or Direction)
|
Convertible Notes (US$)
16 - Acquisition or disposition under a prospectus exemption
|
+$200,000 vol |
$200,000 | |
| Filed 2026-03-04 20:39 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes (US$)
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
$25,000 | |
| Filed 2026-03-04 20:37 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Newlin, William R.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Newlin Investment Company 1, LLC (Control or Direction)
|
Convertible Notes (US$)
16 - Acquisition or disposition under a prospectus exemption
|
+$100,000 vol |
$100,000 | |
| Filed 2026-03-04 20:34 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes (US$)
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
$25,000 | |
| Filed 2026-03-04 20:29 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
||
| Filed 2026-03-04 20:28 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Newlin, William R.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Newlin Investment Company 1, LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$100,000 vol |
||
| Filed 2026-03-04 20:27 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Hathaway, John J.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: STX Partners, LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$200,000 vol |
||
| Filed 2026-03-04 20:24 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
||
| Filed 2026-03-04 15:01 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Newlin, William R.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Newlin Investment Company 1, LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$100,000 vol |
$100,000 | |
| Filed 2026-03-04 15:01 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Newlin, William R.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Newlin Investment Company 1, LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$100,000 vol |
||
| Filed 2026-03-04 15:01 Tx date 2024-12-11 |
$SHRX
Sharp Therapeutics Corp. |
Newlin, William R.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Newlin Investment Company 1, LLC (Control or Direction)
|
Convertible Notes
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2026-03-04 14:59 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Hathaway, John J.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: STX Partners, LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$200,000 vol |
$200,000 | |
| Filed 2026-03-04 14:59 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Hathaway, John J.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: STX Partners, LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$200,000 vol |
||
| Filed 2026-03-04 14:59 Tx date 2024-12-11 |
$SHRX
Sharp Therapeutics Corp. |
Hathaway, John J.
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: STX Partners, LLC (Control or Direction)
|
Convertible Notes
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2026-03-04 14:58 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
||
| Filed 2026-03-04 14:58 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
$25,000 | |
| Filed 2026-03-04 14:57 Tx date 2024-12-11 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2026-03-04 14:55 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
$25,000 | |
| Filed 2026-03-04 14:55 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |